No Data
No Data
Guojian Pharmaceutical Completes Psoriasis Drug Clinical Trial
Sunshine Guojian Pharmaceutical's recombined anti-IL-4Rα humanized monoclonal antibody injection (611) for the treatment of chronic sinusitis with nasal polyps Phase II clinical study achieved the main endpoint.
Shanghai, August 9, 2024 / PRNewswire / - Today, Sunshine Guojian Pharmaceutical (Stock Code: 688336.SH) announced that the Phase II clinical study of the company's independently developed recombinant humanized anti-IL-4Rα monoclonal antibody injection (Research and development code: 611) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) has achieved its primary endpoint. The study included 100 CRSwNP subjects who were randomly assigned to the experimental drug Group A (611 300mg Q2W), experimental drug Group B (611 450mg Q4W), and safety control group at a ratio of 1: 1: 1.
Sunshine Guojian Pharmaceutical (688336.SH): SSGJ-608 has successfully achieved all efficacy endpoints in Phase III clinical trials for psoriasis, accelerating the listing process.
Sunshine Guojian Pharmaceutical (688336.SH) announced a reorganization of the injection of anti-IL-17A humanized monoclonal antibodies (...
Sunshine Guojian Pharmaceutical (688336.SH): The Phase III clinical trial of the recombinant anti-IL-17A fully humanized monoclonal antibody injection for the treatment of moderate to severe plaque psoriasis has achieved all efficacy endpoints.
On August 9th, Gelunhui reported that Sunshine Guojian Pharmaceutical (688336.SH) completed the unblinding and final statistical analysis of the key pivotal Phase III clinical trial evaluating the efficacy and safety of SSGJ-608, a humanized monoclonal antibody injection targeting IL-17A, for the treatment of moderate to severe plaque psoriasis in Chinese adults. The trial was multicenter, randomized, double-blind, and placebo-controlled. All primary efficacy endpoints (PASI75 and sPGA0/1) were met.
Sunshine Guojian Pharmaceutical (688336.SH) granted 5.1745 million restricted stocks to 92 incentive objects.
Sunshine Guojian Pharmaceutical (688336.SH) announced that the company has approved the "Restricted Stock Agreement for the year 2024"...
Declining Stock and Decent Financials: Is The Market Wrong About Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHSE:688336)?
No Data